We also know that some of the most important medical breakthroughs
often result from collaborative R&D agreements and from
partnerships. To find potential new therapies for patients we look
both inside and outside AbbVie for promising discoveries. We partner
and collaborate with peer companies, universities, non-governmental
organisations, as well as other relevant groups, to help find
solutions for patients around the globe—because we recognise there are
times when we can accomplish more together than alone.
In early 2017, AbbVie announced a research partnership with Genuity
Science (Ireland) to undertake a landmark population genomics alliance
in Ireland. The 15-year project aims to sequence the genomes of 45,000
participants to identify novel targets and advance the clinical
development of better treatments for a range of serious diseases. The
collaboration will focus on key AbbVie therapeutic areas including
oncology, neuroscience and immunology that affect hundreds of
thousands of people in Ireland and hundreds of millions worldwide.
AbbVie is committed to research in Ireland. In 2015, a joint
investment of €10 million by the Department of Jobs, Enterprise, and
Innovation through Science Foundation Ireland (SFI) in a partnership
with AbbVie was announced involving two new therapeutic research
partnerships in Ireland. The collaborations, which will each
investigate disease markers and potential targets against which new
drugs may be developed, involve serious illnesses such as Crohn’s
disease, rheumatoid arthritis, psoriasis and multiple sclerosis.
Researchers at the SFI APC Microbiome Institute in University College
Cork and at the Trinity Biomedical Sciences Institute in Trinity
College Dublin are involved.